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Abstract
A qualitative method, involving supported liquid–liquid extraction (SLE) and ultra high
pressure liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS–MS),
was developed for the rapid tentative identification of various drugs of abuse in urine. In this
study, 28 drugs and metabolites were covered by the screening procedure. Before analysis,
urine samples were extracted by SLE and good extraction recoveries were obtained for most
investigated compounds. The UHPLC strategy was then selected for the rapid separation of
amphetamines, cocaine, opiates and related compounds in urine. Using columns packed
with sub-2 lm particles, analysis time was reduced down to 2 min, while maintaining
acceptable performance. Finally, the detection was by tandem MS operating in the single
reaction monitoring (SRM) mode. The most intense transition was selected for the different
drugs and SRM dwell times set at 5 ms, to maintain sufficient data points across the narrow
UHPLC peaks. The tentative identification of the drugs of interest, including amphetamines,
opiates and cocaine, was based on both, retention times and mass spectrometry information.
With the proposed method, limits of detection were estimated at about 1 ng mL-1 and the
applicability was assessed by successfully analyzing several samples of drug abusers. Finally,
this study demonstrates the potential of UHPLC coupled to tandem MS for the rapid screening
of drugs of abuse in urine.
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Introduction
The determination of the abuse of
several drugs and illicit substances is
frequently performed in urine since large
volumes of sample is available, and its
collection is easy and non-invasive [1–3].
In addition, urine testing provides a rel-
atively long detection window for drugs.
However, the latter are mostly excreted
as metabolites, parent drugs being gen-
erally found in trace amounts so that
very sensitive methods are needed for
their analysis. Usually, drugs of abuse in
urine are screened by immunochemical
techniques and positive samples are fur-
ther conﬁrmed by hyphenated tech-
niques such as LC-MS or GC-MS.
Because no pre-derivatization step is
required, there is an increased use of
liquid chromatography coupled to MS
operating in the single or tandem mode
(LC-MS or LC-MS–MS) for the analysis
of drugs in toxicological and forensic
analyses [4, 5]. Indeed, such an approach
provides more speciﬁc information on
substance identity, with lower detection
limits and less interference, compared to
immunoassays.
Recently, some improvements were
brought to conventional LC to speed up
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the analytical process. It appears that
columns packed with sub-2 lm particles
and working under ultra high pressure
(UHPLC) have emerged as an attractive
approach for high throughput screen-
ing, providing faster separations with-
out compromising chromatographic
resolution or MS sensitivity [6, 7].
Therefore, UHPLC-MS–MS strategy is
often employed, particularly in the
ﬁelds of bioanalysis (determination of
various drugs and metabolites in bio-
logical ﬂuids) [8–10] or multi-residue
screening (determination of numerous
contaminants such as pesticides, drugs
or doping agents in complex matrices)
[11–13].
Particularly, several authors reported
the determination of drugs of abuse by
UHPLC-MS–MS. For instance, Lurie
et al. [14] demonstrated the applicability
of UHPLC-MS–MS for the proﬁling of
fentanyl and 16 of its homologues or
heroin and several of its by-products and
precursors [15], but in seized exhibits
only. In the ﬁeld of doping analysis,
UHPLC-MS–MS strategy was employed
for determining between 30 and 130
prohibited substances in urine in a single
analytical run [16–18], using a simple
‘‘dilute and shoot’’ as sample prepara-
tion. Finally, Berg et al. [19] developed
and validated an SPE-UHPLC-MS–MS
method allowing the determination of
six opiates, cocaine and benzoylecgonine
in less than 6 min, reequilibration in-
cluded. They also mentioned that their
method has been routinely used in more
than 2,000 urine samples with two rep-
licates of each sample.
In the present work, the UHPLC-
MS–MS set-up was evaluated for the
rapid screening of several drug of abuse
in urine. Three diﬀerent classes of drugs
were tested: amphetamines and related
substances, opiates including some of
their metabolites, and cocaine and its
major metabolites. Since urine is a
complex matrix with an important
amount of electrolytes, sample prepara-
tion is often mandatory to minimize
matrix eﬀects, and concentrate the ana-
lytes of interest [20, 21]. Due to the
physico-chemical properties (i.e. polarity
and ionization state) of the investigated
drugs, liquid–liquid extraction (LLE)
should be selected [22]. Then, to automate
the sample preparation procedure and
make it coherent with the high
throughput aﬀorded by UHPLC, urine
samples were extracted by supported
liquid–liquid extraction (SLE), a prom-
ising technique appeared in 1997 [23–25],
which can be easily automated in a 96-
well plate format. For the ﬁrst time, we
report the evaluation of SLE as sample
preparation, prior to UHPLC-MS–MS
analysis.
Experimental
Chemicals and Reagents
Methamphetamine, 3,4-methylenedioxy-
amphetamine (MDA), 4-methylenedioxy-
methamphetamine (MDMA, Ecstasy),
3,4-methylenedioxyethylamphetamine
(MDEA),2-methylamino-1-(3,4-methyl-
enedioxyphenyl)butane (MBDB), 2-eth-
ylidene-3,3-diphenyl-1,5-dimethylpyrrol-
idine (EDDP), 6-monoacetylmorphine
(6-MAM), ecgoninemethylester (EME),
benzoylecgonine (BE), cocaethylene, co-
caine and norcocaine were purchased
from Lipomed (Arlesheim, Switzerland).
Dextromethorphan, tramadol, ketamine,
procaine, ephedrine, pseudoephedrine,
norephedrine and nalbuphine were from
Sigma (St. Louis, MO, USA). Papaver-
ine, pethidine, methadone, morphine,
codeine, amphetamine, noscapine and
ethylmorphine were provided by Sieg-
fried (Zoﬁngen, Switzerland). Fentanyl
was obtained from Sintetica (Mendrisio,
Switzerland). The list of the tested drugs
is reported in Table 1.
Formic acid and acetonitrile (ACN)
were of ULC-MS grade and purchased
from Biosolve (Valkenswaard, Nether-
lands). Ammonium hydroxide was
provided by Sigma-Fluka (Buchs, Swit-
zerland). Water was obtained from a
Milli-Q Water Puriﬁcation System from
Millipore (Bedford, MA, USA). Ammo-
nia buﬀer 10 mM was prepared with an
adapted volume of ammonium hydroxide
and the pH adjusted to 9.0 with formic
acid. Finally, pH was measured with a
Metrohm pH meter (Herisau, Switzer-
land). After veriﬁcation with Phoebus
software (Analis, Namur, Belgium), the
prepared buﬀer has a buﬀer capacity
higher than 5 mM pH-1 unit.
Urine samples from drug abusers and
blank urine samples from healthy
volunteers were provided by Dr. Marc
Fathi from HUG (Geneva University
Hospitals, Switzerland). The samples
were stored at -18 C prior to extrac-
tion and analysis.
Extraction Procedure
The extraction of drugs from urine was
carried out by supported liquid–liquid
extraction (SLE). Before extraction,
urine was ﬁltered through a nylon ﬁlter
0.45 lm 9 47 mm and procaine was
added at a concentration of 10 ng mL-1,
as internal standard. The SLE procedure
was performed on Merck Extrelut NT3
cartridges (Darmstadt, Germany) which
contain a modiﬁed form of diatoma-
ceous earth. No pre-treatment of the
cartridge was necessary. In a ﬁrst in-
stance, 1 mL of 250 mM borate buﬀer at
pH 9.0 was added into 2 mL of sample
urine and vortexed for 30 s. The 3 mL
solution was loaded on the SLE car-
tridge (such volume was suitable for
loading, to avoid saturation of the sor-
bent bed, as recommended by the man-
ufacturer) and equilibrated for 10 min.
Elution was with 15 mL ethyl acetate.
The sample solution was then evapo-
rated to dryness at 40 C under a stream
of nitrogen. Finally, the dried samples
were reconstituted in 200 lL HCl 10-4
M prior injection in the UHPLC-MS–
MS system.
Matrix eﬀects arising from the SLE-
UHPLC-MS–MS procedure were eval-
uated in terms of process eﬃciency (PE),
according to a procedure originally
described by Matuszewski et al. [26] and
recently updated by Marchi et al. [27]. It
is noteworthy that the determined PE
corresponds to both matrix eﬀects aris-
ing from sample preparation and elec-
trospray ionization alteration. For its
evaluation, a urine sample spiked with
all analytes, was extracted several times,
using the SLE approach and compared
to a neat standard solution (target ana-
lytes diluted in pure water) at the target
concentration.
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UHPLC-MS–MS
Instrumentation
Analyses were performed on a Waters
Acquity ultra performance liquid chro-
matograph (UPLC) system hyphenated
with a Waters TQD triple quadrupole
mass spectrometer ﬁtted with a Z-spray
electrospray ionization source (Waters,
Milford, MA, USA).
The chromatographic system in-
cluded a binary solvent manager with a
maximum delivery ﬂow rate of
2 mL min-1, a sample manager with an
injection loop volume of 2 lL (full loop
injection), and a column oven set at
30 C. The chromatographic column was
a Waters Acquity BEH C18
(50 9 2.1 mm I.D., 1.7 lm) and a pre-
column Waters Acquity BEH C18
(5 9 2.1 mm I.D., 1.7 lm) was always
used with urine samples. Dwell volume
(Vd) of the UPLC-MS–MS conﬁguration
was estimated at 100 lL with the 2 lL
injection loop. Chromatographic condi-
tions for the separation were as follow:
the analysis was carried out in the gradi-
ent mode at a ﬂow rate of 600 lL min-1
(without splitting) and a temperature of
30 C.Mobile phase consists in a mixture
of aqueous ammonia buﬀer 10 mMat pH
9 (A) and acetonitrile (B). A linear gra-
dient from 10 to 70% B was applied for
2 min. Between analyses, the column was
reequilibrated with the initial conditions
for 1 min (corresponding to ﬁve column
dead volumes).
The TQD instrument operated at
single mass resolution of m/z 0.7 FWHM
(i.e. full width at half maximum), and
possesses an upper mass limit of m/z
2000. The ESCi ionization source was
used in the ESI positive mode and
selected reaction monitoring (SRM) was
performed, using the protonated molec-
ular ion of each compound as the pre-
cursor and the most intense fragment.
Collision energies and cone voltages
were tuned by infusing individually each
compound at 1 lg mL-1 in pH 9 buﬀer
and at a ﬂow rate of 600 lL min-1.
Optimal cone voltage and collision en-
ergy values were summarized in Table 1
along with the corresponding protonated
molecular ions and fragments. Nitrogen
was used as the drying gas and argon as
collision gas. The capillary voltage and
the source extractor voltages were set at
+3.5 kV and +3 V, respectively. The
source temperature was maintained at
150 C, the desolvatation gas tempera-
ture and ﬂow at 300 C and 800 L h-1,
respectively, and the cone gas ﬂow at
40 L h-1. The collision gas ﬂow was set
at 0.2 mL min-1 of Argon and entrance
and exit potentials, respectively, adjusted
to 1 and 0.5 V. Finally, dwell time and
inter-channel delay were set to 5 ms, to
maintain enough data points across the
narrow peaks produced by UHPLC.
Data acquisition, data handling and
instrument control were performed by
Masslynx v4.1 Software (Waters).
Results and Discussion
Evaluation of the Extraction
Procedure
Direct analysis ofurine samples byLC-MS
often results in ion suppression due to
interference from endogeneous or co-
eluting exogeneous compounds. There-
fore, a sample preparation is often
performed in order to avoid these adverse
eﬀects. When dealing with the determina-
tion of forensic drugs in biological ﬂuids,
liquid–liquid extraction (LLE) is generally
the techniqueof choice forproducing clean
extracts that can be directly injected into
the LC-MS system [28].
Table 1. Precursor ions, MS–MS transitions, cone voltages and collision energies for the
selected drugs along with the retention times from the UHPLC-MS–MS method
Compound [M + H]+ MS2 R.T.
(min)
Cone
voltage
(V)
Collision
energy
(eV)
Amphetamines and related compounds
Amphetamine 136 119 0.98 20 12
Ephedrine 166 148 0.82 20 20
Ketamine 238 125 1.55 25 30
MBDB 208 135 1.23 25 18
177 25 10
MDA 180 163 0.96 20 15
135 25 18
MDEA 208 163 1.15 20 14
MDMA 194 79 1.03 25 25
Methamphetamine 150 119 1.06 20 15
Norephedrine 152 134 0.70 20 14
Pseudoephedrine 166 148 0.82 20 20
Opioids and metabolites
6-Monoacetylmorphine
(6-MAM)
328 58 1.11 40 30
165 1.11 40 30
Codeine 300 165 1.09 50 35
Dextromethorphan 272 215 1.86 30 20
EDDP 278 234 1.74 50 25
Ethylmorphine 314 165 1.24 50 35
Fentanyl 337 105 1.95 40 25
Methadone 310 105 2.09 25 35
157 0.90 40 30
Morphine 286 185 0.85 40 35
Nalbuphine 358 69 1.69 30 35
Noscapine 414 220 1.84 50 25
Papaverine 340 202 1.41 50 25
Pethidine 248 70 1.56 45 30
Tramadol 264 58 1.54 25 20
Cocaine and metabolites
Benzoylecgonine (BE) 290 168 0.71 35 19
Cocaethylene 318 82 1.82 35 30
Cocaine 304 182 1.65 35 17
Ecgonine methylester (EME) 200 82 0.60 35 31
168 35 19
Norcocaine 290 136 1.44 30 25
Internal standard
Procaine 237 100 1.26 70 10
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Taking into account the well-known
drawbacks of LLE (i.e. formation of
emulsion, poor phase separation, rela-
tively high solvent consumption, low
degree of automation and labour-inten-
sive procedure), the extraction of drugs
from urine was carried out, in the pres-
ent study, by supported liquid–liquid
extraction (SLE) [23–25], to simplify and
automate the procedure. Basically, SLE
consists in the adsorption of the aqueous
samples on diatomaceous earth followed
by the application of a non-miscible
solvent through the cartridge with sub-
sequent extraction and elution of the
analytes. Finally, SLE allows faster
sample preparation than liquid–liquid
extraction, there is no need for phase
separation avoiding emulsion problems
and is available in 96-well plate format
for high throughput sample preparation.
In the case of a multi-component
analysis (i.e. 28 compounds in our case),
the sample preparation is one of the
most critical steps of the whole analytical
process, because compounds often pos-
sess diﬀerent physico-chemical proper-
ties, as illustrated in Table 2 where
dissociation constant and lipophilicity
have been indicated for each analyte.
The simultaneous extraction of all these
compounds from urine should thus be
generic which usually involves a com-
promise in the selection of experimental
conditions for satisfactory recoveries of
each class of compounds.
In the case of SLE, the most critical
parameter for increasing recovery is the
pH at which urine is loaded on the SLE
cartridge. Similarly to LLE, it should be
adjusted to have the highest proportion
of un-dissociated analytes in the aqueous
extract. In the present study, the pH of
urine was set to a compromise value of
9.0. Indeed, as most of the investigated
drugs of abuse are basic, with pKa in the
range 6.3–10.8, a basic pH value (beyond
pKa +2) should be employed to have the
analytes of interest under their neutral
form. However, there are some excep-
tions in the set of investigated com-
pounds, and particularly, the amphoteric
nature of morphine necessitates careful
adjustment of pH within the range 6.9–
9.0 [29] to ensure that it was in the
appropriate form (as neutral as possible)
for further elution with ethyl acetate. A
similar problem was also observed with
related substances (containing both
acidic phenol and basic amine groups)
such as 6-MAM and nalbuphine, as
example. For these reasons, and in
agreement with data given in Table 2,
the pH was adjusted to 9.0, as a com-
promise which is certainly not the opti-
mal value for amphetamines and related
compounds.
For each extracted compound, the
process eﬃciencies of SLE were calcu-
Table 2. Physico-chemical properties of the investigated drugs of abuse. The pKa, log P and log D values were calculated using Advanced
Chemistry Development (ACD/Labs) Software V8.14 for Solaris
pKa log P log D (pH 8) log D (pH 9) log D (pH 10)
Amphetamines and related compounds
Amphetamine 9.94 1.8 -0.11 0.82 1.53
Ephedrine 9.38 1.05 -0.33 0.52 0.96
Ketamine 6.46 2.18 2.17 2.18 2.18
MBDB 10.46 2.33 -0.03 0.87 1.75
MDA 9.94 1.66 -0.25 0.68 1.39
MDEA 10.34 2.33 0.07 0.99 1.84
MDMA 10.32 1.8 -0.45 0.47 1.31
Methamphetamine 10.38 1.94 -0.36 0.55 1.41
Norephedrine 8.47 0.8 0.21 0.68 0.77
Pseudoephedrine 9.38 1.05 -0.33 0.52 0.96
Opiates and metabolites
6-Monoacetylmorphine (6-MAM) 7.96(b)/9.46(a) 1.32 0.98 1.13 0.64
Codeine 8.25 1.2 0.76 1.13 1.19
Dextromethorphan 9.13 4.11 2.95 3.74 4.06
EDDP 7.71 5.51 5.33 5.49 5.51
Ethylmorphine 8.25 1.73 1.29 1.66 1.72
Fentanyl 9.06 3.89 2.79 3.55 3.84
Methadone 9.05 4.2 3.12 3.87 4.15
Morphine 8.26(b)/9.50(a) 0.43 -0.04 0.23 -0.2
Nalbuphine 7.35(b)/9.39(a) 1.78 1.68 1.63 1.08
Noscapine 6.32 2.82 2.82 2.82 2.82
Papaverine 6.32 3.74 3.73 3.74 3.74
Pethidine 8.58 2.35 1.67 2.21 2.33
Tramadol 9.6 2.51 0.91 1.81 2.36
Cocaine and metabolites
Benzoylecgonine 10.82(b)/3.35(a) 2.71 0.21 0.21 0.16
Cocaethylene 9.04 3.61 2.53 3.29 3.56
Cocaine 8.97 3.08 2.07 2.79 3.04
Ecgonine methylester 9.57 -0.23 -1.8 -0.9 -0.37
Norcocaine 9.02 2.78 1.72 2.47 2.74
Internal standard
Procaine 9.24 2.36 1.11 1.93 2.29
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lated by comparing peak area measured
in urine samples spiked with a known
amount of reference substance and that
of an un-extracted standard aqueous
solution at the same concentration. This
experiment was repeated sixfold and
data for process eﬃciencies and corre-
sponding standard deviations have been
reported in Table 3. Procaine was cho-
sen as the internal standard as it pos-
sesses a pKa close to that of the
investigated analytes but also since it is
completely metabolized in humans and
cannot be found in urine. For amphet-
amine and related substances, process
eﬃciencies were in the range 53–65%
since at pH 9, only a fraction of these
basic compounds was neutral (estimated
pKa are in average equal to 10) and be-
cause of their high polarity (calculated
log D at pH9 always lower than 1, except
ketamine). For opiates, cocaine and their
metabolites, higher process eﬃciencies
(between 71 and 92%) were obtained
because of the higher hydrophobicity of
these compounds (calculated log D at
pH 9 were systematically higher than 1,
except for a few compounds). Only
morphine presented a lower process
eﬃciency, of 65%, which could be
attributed to the amphoteric nature of
this compound, with very weak acidic
properties and its hydrophilicity even at
pH 9 (log D of 0.23), compared to other
opiates.
Optimization of UHPLC-MS–
MS Analysis
Chromatographic Conditions
As discussed previously, the 28 investi-
gated drugs of abuse are mainly basic,
with pKa around 9–10. Therefore, the
pH of the UHPLC separation needs to
be carefully selected to attain suﬃcient
chromatographic selectivity and reten-
tion, without compromising MS sensi-
tivity. Usually, LC-MS is performed in
acidic conditions, using 0.1% formic
acid as mobile phase additive, while the
use of alkaline conditions was only
scarcely reported, because it is believed
that compounds of interest should be
under their ionized form for eﬃcient
ionization in ESI mode. It was recently
demonstrated that alkaline conditions
present some obvious beneﬁts in LC-MS
of basic drugs, both from a chromato-
graphic point of view (i.e. higher reten-
tion and improved selectivity) and MS
sensitivity (i.e. better signal-to-noise be-
cause of the improved mobile phase de-
solvatation in presence of a high
percentage of organic modiﬁer) [19, 30].
Therefore, a pH value of 9 was selected
as a good compromise between suﬃcient
retention/selectivity and elevated MS
sensitivity. In these conditions, interfer-
ences with un-retained sample matrix
components (i.e., matrix eﬀect) inducing
ion suppression or enhancement were
also strongly reduced. To ensure method
stability at this relatively high pH,
the selected chromatographic column
(Waters Acquity BEH) was a hybrid mate-
rial with hydrophobic ethylene groups
present throughout the particle back-
bone, preventing the silica units from
dissolution [31]. This material is stable
within the range 1 < pH < 12 and can
thus be safely used at pH 9.
To analyze the compounds of interest
presenting a wide polarity range, a gen-
eric gradient from 10 to 70% ACN was
carried out in 2 min. Because the column
dead time was around 0.2 min (50 9
2.1 mm column operating at a ﬂow rate
of 600 lL min-1), this gradient time
corresponds to an average retention
factor during gradient elution, ke around
3, which provides a good compromise
between expected resolution and analysis
time, as discussed elsewhere [32]. Despite
a very short analysis time, all drugs of
abuse were eluted during the gradient
run, after un-retained sample matrix
components. Indeed, taking into account
the system dwell time of 0.16 min and
column dead time of 0.20 min, the
investigated compounds should possess
analysis times at least equal to 0.36 min,
which is the case since the lowest re-
tained compound, ecgonine methylester
Table 3. Mean process eﬃciencies (n = 6) obtained after SLE of the diﬀerent drugs
Mean recovery
(%) (n = 6)
Standard
deviation (%)
Amphetamines and related compounds
Amphetamine 55 1
Ephedrine 59 3
Ketamine 65 2
MBDB 59 3
MDA 53 5
MDEA 63 5
MDMA 62 2
Methamphetamine 60 6
Norephedrine 54 2
Opiates and metabolites
6-MAM 75 9
Codeine 80 5
Dextromethorphan 89 6
EDDP 86 3
Ethylmorphine 86 9
Fentanyl 89 7
Methadone 80 2
Morphine 65 6
Nalbuphine 92 9
Norcocaine 80 4
Noscapine 92 7
Papaverine 83 10
Pethidine 85 8
Tramadol 81 4
Cocaine and metabolites
BE 71 7
Cocaethylene 86 9
Cocaine 88 3
EME 81 4
Norcocaine 83 6
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is eluted at 0.60 min (corresponding to
an elution composition of ca. 15%
ACN).
Detection Conditions
Because of the narrow peaks aﬀorded by
fast gradient in UHPLC (i.e. around
2–3 s in our conditions [31]), and the
important number of drugs of abuse
investigated, it is mandatory to ade-
quately adjust the SRM dwell time and
inter-channel delay of the MS–MS
instrument. In the present study, the
SRM dwell time and inter-channel delay
were both set to their minimal value (i.e.
5 ms) to gather maximal information. In
addition, to ensure a suﬃcient acquisi-
tion rate providing suitable peak shape,
it is possible to deﬁne various time-
schedule windows containing diﬀerent
SRM channels and time intervals, as it is
often reported for multi-residue screen-
ing. Therefore, sequential time-schedule
windows (i.e. 18 drugs followed in the
time range 0–1.5 min and 10 other ana-
lytes between 1.5 and 3 min) were
implemented to correctly deﬁne chro-
matographic peaks with a SRM dwell
time of 5 ms.
For each compound, the most suit-
able SRM transition was carefully se-
lected. Because no signiﬁcant adducts
were observed, the protonated ion
([M + H]+) was selected as precursor
ion and the most abundant collision in-
duced dissociation (CID) fragment
monitored. In some particular cases,
such as for MDEA, MBDB, morphine
and norcocaine, two predominant tran-
sitions were followed. For amphetamine
and related substances, the fragments of
interest generally corresponded to the
cleavage of C–N bond. For ephedrine,
the major fragments corresponded to the
loss of water. Isobaric MBDB and
MDEA with mass to charge ratios (m/z)
of 208 shared the same m/z 135 fragment
but were eluted with diﬀerent retention
times (i.e. 1.15 and 1.23 min), as re-
ported in Table 1. In addition, m/z 163
fragment was speciﬁc to MDEA whilst
m/z 177 fragment was speciﬁc to MBDB.
For noscapine, the major fragment was
m/z 220, as reported elsewhere [33]. For
morphine, fragments 157 and 185 were
followed, in agreement with other stud-
ies [15]. For fentanyl as well as for
methadone, the major fragments corre-
sponded to a phenethyl group (m/z 105)
[34]. The fragment m/z 70 of pethidine
most probably originated from the
fragmentation of the piperidine ring. For
tramadol, the fragment m/z 58 corre-
sponded to C3H8N
+. A similar fragment
was observed for 6-MAM, the major
metabolite of heroin, along with a m/z
165 fragment that corresponded to
C13H9
+ [35]. The same fragment was
also monitored for ethylmorphine and
codeine. The major fragment of EDDP,
with m/z 234, was due to the consecutive
losses of a methyl and an ethyl group
[36]. For papaverine, the m/z 202 frag-
ment was obtained after the loss of
dimethoxybenzene moiety [37]. For
cocaine and its metabolites [38], the
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Fig. 1. Selected reaction monitoring chromatograms obtained for extracted spiked urine
samples at 10 ng mL-1. a Sample containing amphetamine and related substances. b Sample
containing opiates and some metabolites. c Sample containing cocaine and its main metabolites
but also the internal standard, procaine. In these ﬁgures, X-axis is time (min) and Y-axis is
intensity (counts)
1378 Chromatographia 2009, 70, November (No. 9/10) Original
fragments were either m/z 82 (C5H8N
+)
for cocaethylene and EME, or corre-
sponded to the loss of benzoic acid to
give fragments with m/z 168 (norcaine
and BE) or 182 (cocaine). BE and nor-
cocaine both shared the transition m/z
290 ? m/z 168 although an intense
fragment with m/z 136 (C8H10NO
+) was
only observed for norcocaine. In addi-
tion, these two compounds were eluted
with diﬀerent retention times (i.e. 0.71
and 1.44 min), as reported in Table 1.
Evaluation of the proposed
SLE-UHPLC-MS–MS Method
The chromatograms of the investigated
drugs of abuse are presented in Fig. 1
and retention times listed in Table 1. As
shown, all the selected substances could
be accurately identiﬁed, based on MS
data (m/z, fragment) and retention time,
except ephedrine and pseudoephedrine
which could not be discriminated from
each other since they have the same m/z
ratio, a similar fragmentation pathway
and were co-eluted with the generic
gradient conditions.
The method selectivity was evaluated
by analyzing diﬀerent negative urine
samples (n = 6). Each sample was trea-
ted to highlight the presence of potential
interfering compounds. For each MRM
transition, no interferences were found
at the retention times corresponding to
tested substances.
In this work, the limits of detection
(LOD) were evaluated in spiked urine
samples after SLE extraction, for a sig-
nal-to-noise ratio (S/N) of about 3. At
the lowest tested concentration for
spiked urine samples (i.e. 1 ng mL-1),
S/N ratios of all compounds remained
always superior to 3, allowing the identi-
ﬁcation of all tested compounds in urine.
Case Study: Application
to Real Urine Samples
Ten real case samples were evaluated
with the screening method to evaluate its
applicability for routine applications.
The selected urine samples also included
negative urines certiﬁed after a routine
LC-MS analysis. As example, Fig. 2
presents the results obtained for the
analysis of urine declared positive for
opiates. The UHPLC-MS–MS proﬁle of
this urine conﬁrmed the presence of
morphine, codeine, noscapine and
6-MAM which indicated a probable
consumption of heroin. In addition, this
urine contained an important quantity of
methadone, widely used in heroin sub-
stitution treatment programme, and its
main metabolite, EDDP. Finally, the
sample also included fentanyl, which can
serve as a direct pharmacological sub-
stitute for heroin in opiate dependent
individuals and a certain amount of
tramadol, an analgesic. This example
demonstrated the important number of
substances that can be found in case of
toxicological issue.
Conclusion
A method involving supported liquid–
liquid extraction and ultra high pressure
liquid chromatography coupled to tan-
dem mass spectrometry was developed
for the separation and identiﬁcation of
28 drugs of abuse in urine samples,
including amphetamines, cocaine, opi-
ates and related compounds.
Prior to analysis, urine samples were
extracted by SLE, allowing to minimize
matrix eﬀects and obtain acceptable
process eﬃciencies for most of the
investigated compounds. However,
because of important diﬀerences in
physico-chemical properties of selected
drugs, the pH of the urine was carefully
adjusted and a value of 9 was selected.
Even if not investigated in the present
study, the SLE procedure can be easily
automated, using a 96-well plate format,
to perform a high throughput sample
preparation in agreement with the
UHPLC-MS–MS procedure.
This screening procedure clearly
highlighted the obvious beneﬁts of col-
umns packed with sub-2 lm particles
(UHPLC), since the analysis time was
reduced down to 2 min, maintaining
suitable performance.
Using tandem MS detection operat-
ing in the single reaction monitoring
mode, sensitivity as well as selectivity of
the method were acceptable, and the
ng mL-1 level was reached for all tested
substances.
Finally, the applicability of the
method was successfully assessed by
analyzing several samples of drug abus-
ers, demonstrating unambiguously the
consumption of heroin in some cases.
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Fig. 2. Selected reaction monitoring chromatogram of real urine sample from drug abuser. In
these ﬁgures, X-axis is time (min) and Y-axis is intensity (counts)
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